🔴 Veracyte is trading 7.9% down in pre-market with no clear company-specific catalyst

Veracyte is trading 7.9% down at $38.25, with no clear company-specific catalyst identified for September 22, 2026.

• Its latest major announcement was the September 14 acquisition of Convergent Genomics, adding the UroAmp bladder-cancer testing platform for $150 million upfront plus potential milestone payments.
• The broader market is mixed in pre-market trading, so sentiment does not clearly explain the decline.
• The move may reflect stock-specific trading or delayed reaction, but evidence remains limited.